Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 18/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904509 | 0.87 | LTA4H (0.49) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3628097 | 0.87 | LTA4H (0.56) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1908363 | 0.87 | LTA4H (0.47) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1906776 | 0.86 | LTA4H (0.48) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1901995 | 0.86 | LTA4H (0.56) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1906912 | 0.86 | LTA4H (0.57) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1906998 | 0.85 | LTA4H (0.55) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1907866 | 0.85 | LTA4H (0.49) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1904313 | 0.84 | LTA4H (0.47) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1905478 | 0.84 | LTA4H (0.56) | LTA4HKCNH2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935725-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-03 | — | — | US | claimed |
| EP-2217237-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| WO-2009058347-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| US-8367719-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8344008-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-01 | — | — | US | disclosed |
| US-20110263639-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | Janseen Pharmaceutical NV | 2011-10-27 | — | — | US | disclosed |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-10-20 | — | — | US | disclosed |
| US-7935725-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-03 | — | — | US | disclosed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 2410/4885CYP1A2 2013/4885 |
| US-20110263639-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 2410/4885CYP1A2 2013/4885 |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KCNH2 2410/4885CYP1A2 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.